Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

In August 2020, BHC announced its plan to separate its eye health business, consisting of its Bausch + Lomb global Vision Care, Surgical and Pharmaceuticals businesses, into an independent publicly ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Valeant got into trouble nearly a decade ago after using debt to ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Bausch Health and Goldman Sachs declined to comment to the FT. Bausch + Lomb is headed by Brent Saunders, a longtime pharmaceutical executive known for leading Allergan into a much-hyped but ...

Trukera Medical, whose executive chairman is well-known Orange County executive Jim Mazzo, announced last month that it has been acquired by global eye health company Bausch + Lomb Corp. for an ...

Larry Biegelsen, an analyst from Wells Fargo, assigned the Buy rating on Bausch + Lomb Corporation (BLCO – Research Report). The ...

Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation ...